Sotera Health (NASDAQ:SHC) Updates FY 2025 Earnings Guidance

Sotera Health (NASDAQ:SHC) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.700-0.760 for the period, compared to the consensus earnings per share estimate of 0.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Sotera Health Trading Up 1.5 %

Shares of SHC stock opened at $12.47 on Friday. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.08. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The business’s fifty day moving average price is $13.45 and its 200 day moving average price is $14.51. The firm has a market capitalization of $3.53 billion, a PE ratio of 49.88 and a beta of 1.91.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SHC. Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a research note on Thursday, November 21st. Barclays reduced their price target on shares of Sotera Health from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday. The Goldman Sachs Group began coverage on Sotera Health in a report on Friday, December 6th. They issued a “neutral” rating and a $14.00 price target on the stock. Finally, Citigroup raised their price objective on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Sotera Health currently has a consensus rating of “Moderate Buy” and an average price target of $15.92.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.